MAP3K8 Antibody

說明書

中文名稱：

MAP3K8兔多克隆抗體
貨號：

CSB-PA001760
規格：

￥1090
圖片：
Western Blot analysis of 293 cells using COT Polyclonal Antibody
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P41279
基因名：

MAP3K8
別名：

AURA2 antibody; c COT antibody; Cancer Osaka thyroid oncogene antibody; CCOT antibody; COT antibody; COT proto oncogene serine/threonine protein kinase antibody; EST antibody; ESTF antibody; Ewing sarcoma transformant antibody; FLJ10486 antibody; M3K8_HUMAN antibody; MAP3K 8 antibody; MAP3K8 antibody; MEKK8 antibody; Mitogen activated protein kinase kinase kinase 8 antibody; Mitogen-activated protein kinase kinase kinase 8 antibody; Proto oncogene cCot antibody; Proto-oncogene c-Cot antibody; Serine/threonine protein kinase cot antibody; Serine/threonine-protein kinase cot antibody; TPL 2 antibody; TPL-2 antibody; TPL2 antibody; Tumor progression locus 2 antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Synthesized peptide derived from Human Cot around the non-phosphorylation site of T290.
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產品提供形式：

Liquid
應用范圍：

WB, IHC, IF, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:100-1:300
IF	1:200-1:1000
ELISA	1:40000

Protocols：

Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.
基因功能參考文獻：
1. these data demonstrate that miR-130b represses vascular inflammation via targeting Tpl2 PMID: 28759810
2. Results show that the binding of miR-589-5p to the MAP3K8 3'-UTR inhibits MAP3K8 expression and suppresses CD90+ cancer stem cells characteristics in hepatocellular carcinoma. PMID: 27835990
3. RelAp43 interacts with the p105-ABIN2-TPL2 complex and we observe a strong perturbation of this complex in presence of M protein. PMID: 29084252
4. miRNA-509-3p mimics or inhibitor transfection tests in KGN cells further confirmed that miRNA-509-3p improved oestradiol (E2) secretion by inhibiting the expression of MAP3K8 PMID: 27002000
5. role of p105/Tpl2 signaling in lung homeostasis PMID: 26300007
6. rs1042058 GG Crohn's disease -risk polymorphism in TPL2 results in a gain-of-function by increasing TPL2 expression and signalling, thereby amplifying Pattern recognition receptor -initiated outcomes. PMID: 26215868
7. MAP3K8 is a direct target of miR-144-3p, and miR-144-3p downregulation is a factor in renal cell carcinoma progression through potentiation of MAP3K8 expression. PMID: 27717821
8. Taken together, these results suggest that Cot kinase might play a critical role in Helicobacter pylori type IV secretion apparatus-dependent early IL-8 secretion and CagA-dependent late IL-8 secretion as an alternative signaling molecule in the Erk pathway. PMID: 28361341
9. Studies indicate that Tpl2, a MAP3K, participates in a broad range of cancer-related signaling pathways and induces tumorigenesis and progression of many cancers. PMID: 25723737
10. the results of the present study demonstrated that the miR-509-3p RCC suppressor was a significant regulator of the MAP3K8 oncogene, suggesting that it may have a potential therapeutic role in the treatment of renal cell carcinoma PMID: 25815776
11. findings provide a novel perspective on the role of the IL-33/ST2/COT signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment PMID: 25531326
12. structurally versatile active site significantly impacts the design of potent, low molecular weight COT kinase inhibitors PMID: 25918157
13. TPL2 mediates the phosphorylation of a fraction of nucleophosmin at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state nucleophosmin levels. PMID: 24998852
14. MAP3K8 and miR-17-5p expression were inversely correlated with treatment response PMID: 24819603
15. COT interacts with and phosphorylates Pin1 on Ser16. Consequently, Pin1 Ser16 phosphorylation by COT increases cyclin D1 abundance and enhances tumorigenecity of MCF7 cells. PMID: 24265246
16. Aberrant expression of A-, B-, and C-RAF, and COT is frequent in PTC; increased expression of COT is correlated with recurrence of PTC. PMID: 25674762
17. Tpl2 overexpression and downregulation showed significant stimulatory and inhibitory effects on tumorigenic and metastatic potential of ADI PC cells. PMID: 25274482
18. Following epithelial injury, intestinal myofibroblasts sense innate or inflammatory signals and activate, via Tpl2, the cyclooxygenase-2 (Cox-2)-prostaglandin E2 (PGE2) pathway, which are essential for the epithelial homeostatic response. PMID: 25316791
19. High MAP3K8 expression affects obesity-induced adipose tissue inflammation without systemic effects. PMID: 24586913
20. Tpl2 regulates various inflammatory pathways by activating the ERK mediated MAP kinase pathway in innate immune cells such as macrophages and dendritic cells in humans but not in mice. PMID: 24642963
21. Coregulation of TLR2 and TLR6 expression correlating with local processing of versican, a proteoglycan TLR2/6 agonist linked to carcinoma progression. PMID: 24723682
22. data indicate that Tpl2 kinase is associated with and contributes to disease progression of clear cell renal cell carcinoma PMID: 23982215
23. this report have defined a novel network leading to ERK1/ERK2 activation in cysticfibrosis airway epithelial cells in response to P. aeruginosa that involves both the TPL2 and EGFR protein kinases and contributes to inflammation of CF airways. PMID: 24404585
24. MAP3K8 mediates the phosphorylation and repression of IRF3 homodimers to promote greater transcriptional activity through utilization of IRF3:IRF7 heterodimers. PMID: 24275658
25. High Tpl2 expression is associated with peritoneal dissemination in gastric tumor. PMID: 23828905
26. The protein kinase TPL2 is essential for ERK1/ERK2 activation and cytokine gene expression in airway epithelial cells exposed to pathogen-associated molecular patterns. PMID: 23527104
27. Authors report constitutive activation of MAP3K8 kinase-dependent pathways that regulate the magnitude and extent of inflammatory activity of monocytes/macrophages within myeloma niches. PMID: 23252623
28. TPL2 was found to antagonize oncogene-induced cell transformation and survival through a pathway involving p53 downstream of cJun N-terminal kinase (JNK) and be required for optimal p53 response to genotoxic stress. PMID: 23533274
29. Overexpression of MAP3K8 is associated with early-onset colorectal cancer. PMID: 23322277
30. High TPL2 expression is associated with tumor progression. PMID: 23125217
31. the role of Tpl2 in GPCR-mediated Ca(2+) signaling and cell migration PMID: 21868363
32. Cot protein is responsible for the constitutive Erk1/2 activation in the anaplastic large-cell lymphoma cells. PMID: 21741362
33. OPN knockdown chemosensitized MDA-MB-231 cells to CTX, which is dependent on p38 MAPK pathway activation PMID: 21539449
34. TPL2 kinase plays a critical role in the promotion of androgen depletion-independent prostate cancer progression. PMID: 21267413
35. Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells. PMID: 20945381
36. identification of MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines PMID: 21107320
37. Tensile strain and magnetic particle force application do not induce MAP3K8 and IL-1B differential gene expression in a similar manner to fluid shear stress in human mesenchymal stem cells. PMID: 20603871
38. MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D3 in parallel with activated c-jun during differentiation of human myeloid leukemia cells PMID: 20227498
39. endogenous Tpl2 promotes efficient murine gammaherpesvirus 68 lytic replication through AP-1-dependent upregulation of RTA expression PMID: 19939924
40. Cot protein, expressed in HEK293 cells and immunoprecipitated, was used in a peptide-based substrate screening assay. The results of this assay suggested that Polo-like kinase 1 (Plk1) was a substrate of Cot. PMID: 19804365
41. contributes to LMP1-induced NF-kB signaling downstream of TRAF2 PMID: 11932422
42. suggest that the activation of different signaling pathways by Cot and other MAP3Ks may be regulated separately and may provide evidence for how such discrimination by one member of this kinase family occurs. PMID: 12138205
43. Tpl2 is inhibited by and is a partner of NFkappab p105 PMID: 12667451
44. hKSR-2, a new member of the KSR family, negatively regulates Cot-mediated MAP kinase and NF-kappaB pathway signaling PMID: 12975377
45. the COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity PMID: 14517305
46. optimal TPL-2 stability in vivo requires interaction with ABIN-2 as well as p105 PMID: 15169888
47. Data support a role for MAP3K8 activity in cellular transformation, but suggest that mutational activation of the gene is a rare event in lung cancer. PMID: 15287022
48. phosphorylation of Cot at Thr-290 is necessary but not sufficient for full kinase activity in the MEK/ERK pathway PMID: 15466476
49. Tpl2/Cot is overexpressed in large granular lymphocyte proliferative disorders but not other T-cell neoplasias. PMID: 15575964
50. These results indicate a distinction between TNF Receptor family members CD40 and TNFR1 in their utilization of MAP3Ks, and demonstrate TRAF-dependence of Tpl2 association with the CD40 receptor complex. PMID: 15670770
顯示更多

收起更多
亞細胞定位：

Cytoplasm.
蛋白家族：

Protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase kinase subfamily
組織特異性：

Expressed in several normal tissues and human tumor-derived cell lines.
數據庫鏈接：

HGNC: 6860

OMIM: 191195

KEGG: hsa:1326

STRING: 9606.ENSP00000263056

UniGene: Hs.432453

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human